1. Home
  2. IDYA vs EXG Comparison

IDYA vs EXG Comparison

Compare IDYA & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$32.39

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

EXG

Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

HOLD

Current Price

$9.71

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
EXG
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.9B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IDYA
EXG
Price
$32.39
$9.71
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
$49.67
N/A
AVG Volume (30 Days)
858.2K
533.2K
Earning Date
02-13-2026
01-01-0001
Dividend Yield
N/A
8.27%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$214,834,000.00
N/A
Revenue This Year
$2,688.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5377.66
N/A
52 Week Low
$13.45
$6.78
52 Week High
$39.28
$8.15

Technical Indicators

Market Signals
Indicator
IDYA
EXG
Relative Strength Index (RSI) 41.60 58.32
Support Level $31.54 $9.48
Resistance Level $34.66 $9.76
Average True Range (ATR) 1.38 0.10
MACD -0.32 -0.01
Stochastic Oscillator 16.84 84.21

Price Performance

Historical Comparison
IDYA
EXG

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.

Share on Social Networks: